Nevirapine Viatris (Nevirapine)

Nevirapine binds to a specific hydrophobic pocket on the HIV‑1 reverse transcriptase enzyme, causing a conformational change that blocks the enzyme’s RNA‑dependent and DNA‑dependent DNA polymerase activities. This prevents the conversion of viral RNA into DNA, halting viral replication.

The dosing regimen for nevirapine is individualized by the prescribing clinician based on patient factors, treatment guidelines and combination therapy requirements. Healthcare providers determine the appropriate dose and schedule for each patient.

Nevirapine may be used in pregnancy when the benefits outweigh potential risks, but it requires careful clinical assessment. Breastfeeding while on nevirapine is generally discouraged because the drug can be excreted in breast milk. Consultation with a specialist is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nevirapine belongs to the NNRTI class, offering a distinct mechanism from nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors. Compared with efavirenz, another NNRTI, nevirapine has a different side‑effect profile, particularly a higher risk of skin reactions but lower central nervous system effects.

Nevirapine tablets should be stored at room temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid environments.

Nevirapine Viatris is taken orally, usually with food to reduce gastrointestinal discomfort. The tablets are swallowed whole with a full glass of water, following the dosing schedule prescribed by the healthcare professional.

The most serious risks include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, and potentially life‑threatening liver toxicity. Patients should be monitored for rash, jaundice, or any signs of hepatic dysfunction, and the drug should be discontinued immediately if these occur.

Nevirapine is contraindicated in patients with a known hypersensitivity to the drug or any of its components, and in those with severe hepatic impairment. Caution is also advised for individuals with a history of severe skin reactions to NNRTIs.